Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) EBITDA Margin (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed EBITDA Margin for 13 consecutive years, with 6237.62% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 21198.0% to 6237.62% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8486.58% through Dec 2025, down 137485.0% year-over-year, with the annual reading at 10578.81% for FY2025, 781922.0% down from the prior year.
  • EBITDA Margin hit 6237.62% in Q4 2025 for Vistagen Therapeutics, up from 7520.93% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 90940.0% in Q1 2025 to a low of 42802.56% in Q1 2022.
  • Historically, EBITDA Margin has averaged 2075.44% across 5 years, with a median of 5615.66% in 2022.
  • Biggest five-year swings in EBITDA Margin: tumbled -4139555bps in 2022 and later surged 9674549bps in 2025.
  • Year by year, EBITDA Margin stood at 2943.85% in 2021, then plummeted by -84bps to 5425.83% in 2022, then soared by 72bps to 1545.01% in 2023, then crashed by -290bps to 6025.64% in 2024, then decreased by -4bps to 6237.62% in 2025.
  • Business Quant data shows EBITDA Margin for VTGN at 6237.62% in Q4 2025, 7520.93% in Q3 2025, and 6188.11% in Q2 2025.